Positive phase 3 results reported in study of Guillain-Barre treatment

Annexon Biosciences has announced positive topline results from a phase 3, randomized placebo-controlled clinical trial examining an investigational monoclonal antibody in those with Guillain-Barré syndrome.
According to a company press release, the study met its primary endpoint, with a dose of ANX005 at 30 mg/kg achieving a 2.4-fold improvement on the GBS-disability scale (GBS-DS) at week 8. The treatment also demonstrated superiority compared with placebo on key secondary endpoints including early gains in muscle strength measured by Medical Research Council sum score at day 8 and at

Annexon Biosciences has announced positive topline results from a phase 3, randomized placebo-controlled clinical trial examining an investigational monoclonal antibody in those with Guillain-Barré syndrome.
According to a company press release, the study met its primary endpoint, with a dose of ANX005 at 30 mg/kg achieving a 2.4-fold improvement on the GBS-disability scale (GBS-DS) at week 8. The treatment also demonstrated superiority compared with placebo on key secondary endpoints including early gains in muscle strength measured by Medical Research Council sum score at day 8 and at